Abstract
Many new mothers who need antidepressant or mood-stabilising drug treatment may wish to breastfeed their infants, but are hesitant to do so because of possible harmful effects of the medication on the infant. This article reviews current data on drug excretion into breast milk and the effects on the breast-fed child, and provides recommendations for the use of the different psychotropic drugs in lactating women.
Relevant literature was identified through systematic searches of MEDLINE, EMBASE and the Science Citation Index Expanded (ISI) from 1966 to February 2005. The present knowledge is based on the accumulation of case studies. No randomised controlled trials in breast-fed infants have been performed and there is a lack of long-term follow-up studies.
Use of SSRIs and TCAs (except doxepin) is compatible with breastfeeding. However, if treatment with an SSRI is started in the postpartum period, fluoxetine and citalopram may not be drugs of first choice. With regard to other antidepressants, such as venlafaxine, trazodone, mirtazapine, reboxetine, moclobemide and other MAOIs, very little knowledge exists. Breastfeeding should be avoided while using lithium. Carbamazepine and sodium valproate (valproic acid) are generally better tolerated by the breast-fed infant than lithium. Data on lamotrigine are still sparse. Knowledge is also scarce on the novel antipsychotics and thus recommendations in lactating women cannot be made for these agents. It is unwise to expose infants unnecessarily to drugs that may have severe adverse effects. As such, clozapine should probably be avoided because of the risk of agranulocytosis.
Our knowledge of the impact of drug exposure through breast milk is still limited. Infant drug exposure is, however, generally higher during pregnancy through placental passage than through breast milk. Despite the low dosage transfered to the infant through breast milk, premature infants and infants with neonatal diseases or inherited disturbances in metabolism may be vulnerable to such exposure.
Similar content being viewed by others
References
Watson JP, Elliot SA, Rugg AJ. Psychiatric disorder in pregnancy and the first postnatal year. Br J Psychiatry 1984; 144: 453–62
Kumar R, Robson KM. A prospective study of emotional disorders in child-bearing women. Br J Psychiatry 1984; 144: 35–47
Hendrick V, Smith LM, Hwang S, et al. Weight gain in breastfed infants of mothers taking antidepressant medications. J Clin Psychiatry 2003; 64: 410–2
Moore G, Cohn J, Campbell S. Infant affective responses to mother’s still face at 6 months differentially predict externalizing and internalizing behaviors at 18 months. Dev Psychol 2001; 37: 706–14
Sinclair D, Murray L. Effects of postnatal depression on children’s adjustment to school. Br J Psychiatry 1998; 172: 58–63
Murray L, Sinclair D, Cooper PJ, et al. The socioemotional development of 5-year-old children of postnatally depressed mothers. J Child Psychol Psychiatry 1999; 40: 1259–71
Weinberg M, Tronick E. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59: 53–61
Friel JK, Martin SM, Langdon M, et al. Milk from mothers of both premature and full-term infants provides better antioxidant protection than does infant formula. Pediatr Res 2002; 51: 612–8
A Joint WHO/UNICEF Statement. Protecting, promoting and supporting breastfeeding: the special role of maternity services. Geneva: WHO, 1989
American Academy of Pediatrics. Breastfeeding and the use of human milk. Pediatrics 1997; 100: 1035–9
Golding J, Emmett P, Rogers I. Gastroenteritis, diarrhoea and breast feeding. Early Hum Dev 1997; 49 Suppl.: s83–103
van Odijk J, Kull I, Borres M, et al. Breast feeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations. Allergy 2003; 58: 833–43
Foster S, Slade P, Wilson K. Body image, maternal fetal attachment, and breast feeding. J Psychosom Res 1996; 41: 181–4
Uvnas-Moberg K. Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinology 1998; 23: 819–35
Liestøl K, Rosenberg M, Walloe L. Breast-feeding practice in Norway 1860–1984. J Biosoc Sci 1988; 20: 45–58
Ryan AS, Wenjun Z, Acosta A. Breastfeeding continues to increase into the new millennium. Pediatrics 2002; 110: 1103–9
Newport D, Wilcox M, Stowe Z. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol 2001; 25: 177–90
Wisner K, Perel J, Findling R. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153: 1132–7
Spigset O, Hagg S. Excretion of psychotropic drugs into breastmilk; pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9(2): 111–34
Misri S, Kostaras X. Benefits and risks to mother and infant of drug treatment for postnatal depression. Drug Saf 2002; 25: 903–11
Wisner K, Parry B, Piontek C. Postpartum depression. N Engl J Med 2002; 347: 194–9
Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers’ milk: a comprehensive review of assay methods, pharmacokinetics and safety of breast-feeding. J Psychopharmacol 1999; 13: 64–80
Burt V, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158: 1001–9
Dodd S, Buist A, Norman T. Antidepressants and breast-feeding. Paediatr Drugs 2000; 2: 183–92
Hagg S, Spigset O. Anticonvulsant use during lactation. Drug Saf 2000; 22: 425–40
Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002; 159: 1667–73
Cox JL, Murray D, Chapman G. A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry 1993; 163: 27–31
O MW, Swain AM. Rates and risk of postpartum depression: a meta-analysis. Int Rev Psychiatry 1996; 8: 37–54
Paykel E, Emms E, Fletcher J, et al. Life events and social support in puerperal depression. Br J Psychiatry 1980; 136: 339–46
Eberhard-Gran M, Eskild A, Tambs K, et al. Depression in postpartum and non-postpartum women: prevalence and risk factors. Acta Psychiatr Scand 2002; 105: 426–33
Eberhard-Gran M, Eskild A, Tambs K, et al. Review of validation studies of the Edinburgh Postnatal Depression Scale. Acta Psychiatr Scand 2001; 104: 243–9
Eberhard-Gran M, Tambs K, Opjordsmoen S, et al. Depression during pregnancy and after delivery: a repeated measurement study. J Psychosom Obstet Gynecol 2004; 25: 15–21
Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257–60
O’Hara MW, Zekoski EM, Philipps LH, et al. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol 1990; 99: 3–15
Johanson R, Chapman G, Murray L, et al. The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. J Psychosom Obstet Gynaecol 2000; 21: 93–7
Josefsson A, Berg G, Nordin C, et al. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251–5
Eberhard-Gran M, Tambs K, Opjordsmoen S, et al. A comparison of anxiety and depressive symptomatology in puerperal and non-puerperal women. Soc Psychiatry Psychiatr Epidemiol 2003; 38: 551–6
Klein M, Essex MJ. Pregnant or depressed? The effect of overlap between symptoms of depression and somatic complaints of pregnancy on rates of major depression during second trimester. Depression 1994; 2: 1994–5
O’Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984; 93: 158–71
Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987; 150: 782–6
Brockington I. Postpartum psychiatric disorders. Lancet 2004; 363: 303–10
O’Hara MW, Zekoski E. Postpartum depression: a comprehensive review. In: Kumar R, Brockington I, editors. Motherhood and mental illness. London: Wright, 1988: 17–63
First MB, Spitzer RL, Gibbon M, et al. Structural clinical interview for DSM-IV axis I disorders: patient edition (SCID I/P, version 2.0). New York: New York State Psychiatric Institute, Biometric Research Department, 1995
Emerson C. Thyroid diseases during and after pregnancy. In: Braverman J, editor. Werner and Ingbar’s the thyroid. Philadelphia (PA): Lippincott Company, 1991: 1263–79
Learoyd D, Fung H, McGregor A. Postpartum thyroid dysfunction. Thyroid 1992; 2: 73–80
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: 4th ed. Washington (DC): American Psychiatric Press, 1994
Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143–51
Brockington I, Cernick K, Schofield E, et al. Puerperal psychosis. Arch Gen Psychiatry 1981; 38: 829–33
Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987; 150: 662–73
Bennazzi F. Mood patterns and classification in bipolar disorder. Curr Opin Psychiatry 2006; 19: 1–8
Breitzka R, Sandritter T, Hatzopoulus F. Principles of drug transfer into breastmilk and drug disposition in the nursing infant. J Hum Lact 1997; 13: 155–8
Jensen P, Olesen O, Bertelsen A, et al. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997; 19: 236–9
Kacew S. Adverse effects of drugs and chemicals in breast milk on the nursing infant. J Clin Pharmacol 1993; 33: 213–21
Anderson PO, Pochop SL, Manoguerra AS. Adverse drug reactions in breastfed infants: less than imagined. Clin Pediatr 2003; 42: 325–40
Suri R, Stowe ZN, Hendrick V, et al. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry 2002; 52: 446–51
Stokes P, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19: 1135–250
Kristensen J, Ilett K, Hackett L, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999; 48: 521–7
Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breastmilk. J Clin Pharmacol 1996; 36: 42–7
Isenberg KE. Excretion of fluoxetine in human breast milk [letter]. J Clin Psychiatry 1990; 51: 169
Burch K, Wells B. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992; 89: 676–7
Yoshida K, Smith B, Kumar R. Fluvoxamine in breast-milk and infant development. Br J Clin Pharmacol 1997; 44: 210–1
Wright S, Dawling S, Ashford J. Excretion of fluvoxamine in breast milk [letter]. Br J Clin Pharmacol 1991; 31: 209
Begg E, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999; 48: 142–7
Stowe Z, Cohen L, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 157: 185–9
Misri S, Kim J, Riggs K, et al. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000; 61: 828–32
Ohman R, Hagg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60: 519–23
Spigset O, Carleborg L. Paroxetine level in breast milk [letter]. J Clin Psychiatry 1996; 57: 39
Rampono J, Kristensen J, Hackett L, et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacology 2000; 50: 263–8
Schmidt K, Olesen O, Jensen P. Citalopram and breastfeeding: serum concentration and side effects in the infant. Biol Psychiatry 2000; 47: 164–5
Spigset O, Carleborg L, Ohman R, et al. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997; 44: 236–9
Kristensen J, Ilett K, Dusci L, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998; 45: 453–7
Stowe Z, Owens M, Landry J, et al. Sertraline and desmethylser-traline in human breast milk and nursing infants. Am J Psychiatry 1997; 154: 1255–60
Hagg S, Granberg K, Carleborg L. Excretion of fluvoxamine into breast milk. Br J Clin Pharmacol 2000; 49: 283–8
Kristensen J, Hackett L, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact 2002; 18: 139–43
Altamura A, Moro A, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201–14
Brent N, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr 1998; 37: 41 -4
Lester B, Cucca J, Andreozzi B, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32: 1253–5
Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr 2005; 40: 681–4
Chambers C, Anderson P, Thomas R, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104: e61
Yoshida K, Smith B, Craggs M, et al. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 1998; 172: 175–9
Birnbaum C, Cohen L, Bailey J, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999; 104: e11
Berle JO, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65: 1228–34
Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179: 163–6
Altshuler L, Burt V, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995; 56: 243–5
Epperson C, Anderson G, McDougle C, et al. Sertraline and breastfeeding. N Engl J Med 1997; 336: 1189–90
Mammen O, Perel J, Rudolph G, et al. Sertraline and norser-traline levels in three breastfed infants. J Clin Psychiatry 1997; 58: 100–3
Wisner K, Perel J, Blumer J. Serum sertraline and N-desmethyl-sertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998; 155: 690–2
Dodd S, Stocky A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000; 15: 261–4
Stowe Z, Hostetter A, Owens M, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentration. J Clin Psychiatry 2003; 64: 73–80
Epperson N, Czarkowski KA, Ward-O’Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry 2001; 158: 1631–7
Piontek C, Wisner K, Perel J, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001; 62: 111–3
Brixen-Rasmussen L, Halgrener J, Jorgensen A. Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology 1982; 76: 94–5
Breyer-Pfaff U, Nill K, Entemann A, et al. Secretion of amitriptyline and metabolites into breast milk. Am J Psychiatry 1995; 152: 812–3
Wisner K, Perel J. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991; 148: 1234–6
Wisner K, Perel J. Nortriptyline treatment of breast-feeding women [letter]. Am J Psychiatry 1996; 153: 295
Stancer H, Reed K. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant’s serum. Am J Psychiatry 1986; 143: 1595–600
Schimmell M, Katz E, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29: 479–84
Wisner K, Perel J, Foglia J. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995; 56: 17–20
Ilett K, Lebedevs T, Wojnar-Horton R, et al. The excretion of dothiepin and its primary metabolites in breast milk. Br J Clin Pharmacol 1992 Jun; 33(6): 635–9
Matheson I, Pande H, Alertsen A. Respiratory depression caused by N-desmethyldoxepin in breast milk [letter]. Lancet 1985; II: 1124
Kemp J, Ilett K, Booth J, et al. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmacol 1985; 20: 497–9
Frey O, Scheidt P, von Brenndorff A. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. Ann Pharmacother 1999; 33: 690–3
Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21: 157–71
Buist A, Janson H. Effect of exposure to dothiepin and northiaden in breast milk on child development. Br J Psychiatry 1995; 167: 370–3
Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43: 225–37
Ilett K, Hackett L, Dusci L. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998; 45: 459–62
Ilett K, Kristensen J, Hackett L, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002; 53: 17–22
Hendrick V, Altshuler L, Wertheimer A, et al. Venlafaxine and breast-feeding. Am J Psychiatry 2001; 158: 2089–90
Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol 1986; 22: 367–70
Dodd S, Buist A, Burrows G, et al. Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breastmilk by high-performance liquid chromatography. J Chromatogr B 1999; 730: 249–55
Yapp P, Ilett K, Kristensen J, et al. Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites. Ann Pharmacother 2000; 34: 1269–72
Pons G, Schoerlin MP, Tam YK, et al. Maclobemide excretion in human breast milk. Br J Clin Pharmacol 1990; 29: 27–31
Patrick MJ, Tilstone WJ, Reavey P. Diazepam and breastfeeding. Lancet 1972; I: 542–3
Wesson DR, Cambers S, Harkey M, et al. Diazepam and desmethyldiazepam in breast milk. J Psychoactive Drugs 1985; 17: 55–6
Pons G, Francoual C, Guillet PH, et al. Zolpidem excretion in breast milk. Eur J Clin Pharmacol 1989; 37: 245–8
Matheson I, Sande HA, Gaillot J. The excretion of zopiclone into breast milk. Br J Clin Pharmacol 1990; 30: 267–71
Tunnessen WW, Hertz CG. Toxic effects of lithium in newborn infants: a commentary. J Pediatr 1972; 81: 804–7
Amdsen A. Clinical features and management of lithium poisoning. Med Toxicol Adverse Drug Exp 1988; 3: 18–32
Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998; 59Suppl. 6: 57–64
Schou M. Lithium treatment during pregnancy, delivery, and lactation: an update. J Clin Psychiatry 1990; 51: 410–3
Pynnonen S, Kanto J, Sillanpaa M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol 1977; 41: 244–53
Niebyl JR, Blake DA, Freeman JM, et al. Carbamazepine levels in pregnancy and lactation. Obstet Gynecol 1979; 53: 139–40
Kaneko S, Sato T, Susuki K. The levels of anticonvulsants in breast milk. Br J Clin Pharmacol 1979; 7: 624–7
Kaneko S, Susuki K, Sato T. The problems of antiepileptic medication in the neonatal period: is breast feeding advisable. In: Janz D, editor. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 343–8
Shimoyama R, Ohkubo T, Sugawara K. Monitoring of carbamazepine and carbamazepine 10,11-epoxide in breast milk and plasma by high-performance liquid chromatography. Ann Clin Biochem 2000; 37: 210–5
Piontek C, Baab S, Peindl K, et al. Serum valproate levels in 6 breastfeeding mother-infant pairs. J Clin Psychiatry 2000; 61: 170–2
Nau H, Helge H, Luck W. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. J Pediatr 1984; 104: 627–34
von Unruh GE, Froescher W, Hoffmann F, et al. Valproic acid in breast milk: how much is really there? Ther Drug Monit 1984; 6: 272–6
Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Psychopharmacol 1998; 18: 167–9
Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990; 150: 136–8
Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997; 130: 1001–3
Liporace J, Kao A, D’Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 2004; 5: 102–5
Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 709–13
Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38: 1039–41
Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003; 5Suppl. 2: 7–19
Fenton C, Scott LJ. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs 2005; 19(5): 429–44
Barnas C, Bergant A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid and breast milk [letter]. Am J Psychiatry 1994; 151: 945
Croke S, Buist A, Hackett L, et al. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002; 5: 243–7
Hill RC, McIvor RJ, Wojnar-Horton R, et al. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. J Clin Psychopharmacol 2000; 20: 285–6
Ilett KF, Hackett L, Kristensen J, et al. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother 2004; 38: 273–6
Goldstein D, Corbin L, Fung MC. Olanzapine-exposed pregnancies and lactation: early experiences. J Psychopharmacol 2000; 20: 399–403
Kirchheiner J, Berghøfer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacotherapy 2000; 33: 78–80
Gardiner SJ, Kristensen J, Begg E, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry 2003; 160: 1428–31
Spigset O, Hägg S. Excretion of psychotropic drugs into breast milk: pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9(2): 111–34
Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330–7
Sharma V. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother 2002; 3: 1421–31
Holden J, Sagovsky R, Cox J. Counseling in a general practice setting: a controlled study of health visitor intervention in treatment of postnatal depression. BMJ 1989; 298: 223–6
Wickberg B, Hwang C. Counselling of postnatal depression: a controlled study on a population based Swedish sample. J Affect Disord 1996; 39: 209–16
Dennis CL. Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. J Clin Psychiatry 2004; 65: 1252–65
Ray K, Hodnett E. Caregiver support for postpartum depression. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2002
Misri S, Kostaras X, Fox D, et al. The impact of partner support in the treatment of postpartum depression. Can J Psychiatry 2000; 45: 554–8
MacArthur C, Winter H, Bick D, et al. Effects of redesigned community postnatal care on womens’ health 4 months after birth: a cluster randomised controlled trial. Lancet 2002; 359: 378–85
O’Hara M, Stuart S, Gorman L, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000; 57: 1039–45
Klier C, Muzik M, Rosenblum K, et al. Interpersonal psychotherapy adapted for the group setting in the treatment of postpartum depression. J Psychother Pract Res 2003; 10: 124–31
Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioral counselling in the treatment of postnatal depression. BMJ 1997; 314: 932–6
Dennis C-L, Stewart D. Treatment of postpartum depression, part 1: a critical review of biological interventions. J Clin Psychiatry 2004; 65: 1242–51
Reed P, Sermin N, Appleby L, et al. A comparison of clinical response to electroconvulsive therapy in puerperal and non-puerperal psychoses. J Affect Disord 1999; 54: 255–60
Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk: pharmacokinetic principles and recommendations. Clin Pharmacokinet 1994; 27: 270–89
Wretlind M. Excretion of oxazepam in breastmilk. Eur J Clin Pharmacol 1987; 33: 209–10
Chaudron L, Jefferson J. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000; 61: 79–90
Sharma V, Smith A, Khan M. The relationship between duration of labour, time of delivery, and puerperal psychosis. J Affect Disord 2004; 82: 215–20
Acknowledgements
The authors have no financial or other relationship that might lead to a conflict of interest in this article. This study was supported by the Norwegian Research Council.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eberhard-Gran, M., Eskild, A. & Opjordsmoen, S. Use of Psychotropic Medications in Treating Mood Disorders during Lactation. CNS Drugs 20, 187–198 (2006). https://doi.org/10.2165/00023210-200620030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200620030-00002